BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Borgia SM, Hedskog C, Parhy B, Hyland RH, Stamm LM, Brainard DM, Subramanian MG, Mchutchison JG, Mo H, Svarovskaia E, Shafran SD. Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes. The Journal of Infectious Diseases 2018;218:1722-9. [DOI: 10.1093/infdis/jiy401] [Cited by in Crossref: 98] [Cited by in F6Publishing: 90] [Article Influence: 24.5] [Reference Citation Analysis]
Number Citing Articles
1 Jia Y, Yue W, Gao Q, Tao R, Zhang Y, Fu X, Liu Y, Liu L, Feng Y, Xia X. Characterization of a Novel Hepatitis C Subtype, 6xj, and Its Consequences for Direct-Acting Antiviral Treatment in Yunnan, China. Microbiol Spectr 2021;9:e0029721. [PMID: 34479413 DOI: 10.1128/Spectrum.00297-21] [Reference Citation Analysis]
2 Spearman CW, Dusheiko GM, Hellard M, Sonderup M. Hepatitis C. Lancet. 2019;394:1451-1466. [PMID: 31 DOI: 10.1016/s0140-6736(19)32320-7] [Cited by in Crossref: 108] [Cited by in F6Publishing: 56] [Article Influence: 2.3] [Reference Citation Analysis]
3 Di Stefano M, Ismail MH, Leitner T, Faleo G, Elmnan Adem SA, Elamin MOME, Eltreifi O, Alwazzeh MJ, Fiore JR, Santantonio TA. Genetic Subtypes and Natural Resistance Mutations in HCV Genotype 4 Infected Saudi Arabian Patients. Viruses 2021;13:1832. [PMID: 34578414 DOI: 10.3390/v13091832] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Chang ML, Yang Z, Yang SS. Roles of Adipokines in Digestive Diseases: Markers of Inflammation, Metabolic Alteration and Disease Progression. Int J Mol Sci 2020;21:E8308. [PMID: 33167521 DOI: 10.3390/ijms21218308] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
5 Onorato L, Pisaturo M, Starace M, Minichini C, Di Fraia A, Astorri R, Coppola N. Virological Factors Associated with Failure to the Latest Generation of Direct Acting Agents (DAA) and Re-Treatment Strategy: A Narrative Review. Viruses 2021;13:432. [PMID: 33800289 DOI: 10.3390/v13030432] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Wu BR, Eltahla AA, Keoshkerian E, Walker MR, Underwood A, Brasher NA, Agapiou D, Lloyd AR, Bull RA. A method for detecting hepatitis C envelope specific memory B cells from multiple genotypes using cocktail E2 tetramers. J Immunol Methods 2019;472:65-74. [PMID: 31226262 DOI: 10.1016/j.jim.2019.06.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
7 Mejer N, Galli A, Ramirez S, Fahnøe U, Benfield T, Bukh J. Ribavirin inhibition of cell-culture infectious hepatitis C genotype 1-3 viruses is strain-dependent. Virology 2020;540:132-40. [PMID: 31778898 DOI: 10.1016/j.virol.2019.09.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
8 Chatterjee K, Gupta R, Omar BJ, Gupta P, Kalita D. Genotypic distribution of hepatitis C virus in Uttarakhand. Indian J Med Microbiol 2021:S0255-0857(21)04133-5. [PMID: 34210508 DOI: 10.1016/j.ijmmb.2021.06.009] [Reference Citation Analysis]
9 Huang YC, Huang CF, Liu SF, Liu HY, Yeh ML, Huang CI, Hsieh MH, Dai CY, Chen SC, Yu ML, Chuang WL, Huang JF. The performance of HCV GT plus RUO reagent in determining Hepatitis C virus genotypes in Taiwan. PLoS One 2021;16:e0246376. [PMID: 33513184 DOI: 10.1371/journal.pone.0246376] [Reference Citation Analysis]
10 Ward JC, Bowyer S, Chen S, Fernandes Campos GR, Ramirez S, Bukh J, Harris M. Insights into the unique characteristics of hepatitis C virus genotype 3 revealed by development of a robust sub-genomic DBN3a replicon. J Gen Virol 2020;101:1182-90. [PMID: 32897181 DOI: 10.1099/jgv.0.001486] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Chang ML, Hu JH, Yen CH, Chen KH, Kuo CJ, Lin MS, Lee CH, Chen SC, Chien RN. Evolution of ferritin levels in hepatitis C patients treated with antivirals. Sci Rep. 2020;10:19744. [PMID: 33184464 DOI: 10.1038/s41598-020-76871-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Ceccherini-Silberstein F, Cento V, Di Maio VC, Perno CF, Craxì A. Viral resistance in HCV infection. Curr Opin Virol 2018;32:115-27. [PMID: 30439589 DOI: 10.1016/j.coviro.2018.10.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
13 Muljono DH. Effective drugs on the road to HCV elimination and a therapeutic gap to close. Lancet Gastroenterol Hepatol 2019;4:86-8. [PMID: 30555049 DOI: 10.1016/S2468-1253(18)30417-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Dächert C, Gladilin E, Binder M. Gene Expression Profiling of Different Huh7 Variants Reveals Novel Hepatitis C Virus Host Factors. Viruses 2019;12:E36. [PMID: 31905685 DOI: 10.3390/v12010036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Rodgers MA, Gomathi S, Vallari A, Saravanan S, Lucas GM, Mehta S, Solomon SS, Cloherty GA. Diverse HCV Strains And HIV URFS Identified Amongst People Who Inject Drugs In India. Sci Rep 2020;10:7214. [PMID: 32350342 DOI: 10.1038/s41598-020-64309-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Romero-López C, Berzal-Herranz A. The Role of the RNA-RNA Interactome in the Hepatitis C Virus Life Cycle. Int J Mol Sci 2020;21:E1479. [PMID: 32098260 DOI: 10.3390/ijms21041479] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
17 Mekonnen ZA, Grubor-Bauk B, Masavuli MG, Shrestha AC, Ranasinghe C, Bull RA, Lloyd AR, Gowans EJ, Wijesundara DK. Toward DNA-Based T-Cell Mediated Vaccines to Target HIV-1 and Hepatitis C Virus: Approaches to Elicit Localized Immunity for Protection. Front Cell Infect Microbiol 2019;9:91. [PMID: 31001491 DOI: 10.3389/fcimb.2019.00091] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Spitz N, Barros JJ, do Ó KM, Brandão-Mello CE, Araujo NM. The First Complete Genome Sequences of Hepatitis C Virus Subtype 2b from Latin America: Molecular Characterization and Phylogeographic Analysis. Viruses 2019;11:E1000. [PMID: 31683566 DOI: 10.3390/v11111000] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
19 Chang ML, Chen WT, Hu JH, Chen SC, Gu PW, Chien RN. Altering retinol binding protein 4 levels in hepatitis C: Inflammation and steatosis matter. Virulence 2020;11:1501-11. [PMID: 33135589 DOI: 10.1080/21505594.2020.1838742] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
20 Meshram RJ, Kathwate GH, Gacche RN. Progress, evolving therapeutic/diagnostic approaches, and challenges in the management of hepatitis C virus infections. Arch Virol 2022. [PMID: 35089390 DOI: 10.1007/s00705-022-05375-0] [Reference Citation Analysis]
21 Statler VA, Espinosa C. Management of Hepatitis C in Children and Adolescents. J Pediatric Infect Dis Soc 2020;9:785-90. [PMID: 33043957 DOI: 10.1093/jpids/piaa114] [Reference Citation Analysis]
22 McNaughton AL, Revill PA, Littlejohn M, Matthews PC, Ansari MA. Analysis of genomic-length HBV sequences to determine genotype and subgenotype reference sequences. J Gen Virol 2020;101:271-83. [PMID: 32134374 DOI: 10.1099/jgv.0.001387] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
23 Guntipalli P, Pakala R, Kumari Gara S, Ahmed F, Bhatnagar A, Endaya Coronel MK, Razzack AA, Solimando AG, Thompson A, Andrews K, Enebong Nya G, Ahmad S, Ranaldo R, Cozzolongo R, Shahini E. Worldwide prevalence, genotype distribution and management of hepatitis C. Acta Gastroenterol Belg 2021;84:637-56. [PMID: 34965046 DOI: 10.51821/84.4.015] [Reference Citation Analysis]
24 Galli A, Ramirez S, Bukh J. Lipid Droplets Accumulation during Hepatitis C Virus Infection in Cell-Culture Varies among Genotype 1-3 Strains and Does Not Correlate with Virus Replication. Viruses 2021;13:389. [PMID: 33671086 DOI: 10.3390/v13030389] [Reference Citation Analysis]
25 Chen J, Chiu Y, Lee P, Tung H, Chiu H, Chien S, Cheng P. Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C. Journal of the Formosan Medical Association 2022. [DOI: 10.1016/j.jfma.2022.04.020] [Reference Citation Analysis]
26 Di Maio VC, Barbaliscia S, Teti E, Fiorentino G, Milana M, Paolucci S, Pollicino T, Morsica G, Starace M, Bruzzone B, Gennari W, Micheli V, Yu La Rosa K, Foroghi L, Calvaruso V, Lenci I, Polilli E, Babudieri S, Aghemo A, Raimondo G, Sarmati L, Coppola N, Pasquazzi C, Baldanti F, Parruti G, Perno CF, Angelico M, Craxì A, Andreoni M, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network Group (Vironet C). Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C. Liver Int 2021;41:1802-14. [PMID: 33497016 DOI: 10.1111/liv.14797] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Manso CF, Bibby DF, Lythgow K, Mohamed H, Myers R, Williams D, Piorkowska R, Chan YT, Bowden R, Ansari MA, Ip CLC, Barnes E, Bradshaw D, Mbisa JL. Technical Validation of a Hepatitis C Virus Whole Genome Sequencing Assay for Detection of Genotype and Antiviral Resistance in the Clinical Pathway. Front Microbiol 2020;11:576572. [PMID: 33162957 DOI: 10.3389/fmicb.2020.576572] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
28 Wang R, Suzuki S, Guest JD, Heller B, Almeda M, Andrianov AK, Marin A, Mariuzza RA, Keck ZY, Foung SKH, Yunus AS, Pierce BG, Toth EA, Ploss A, Fuerst TR. Induction of broadly neutralizing antibodies using a secreted form of the hepatitis C virus E1E2 heterodimer as a vaccine candidate. Proc Natl Acad Sci U S A 2022;119:e2112008119. [PMID: 35263223 DOI: 10.1073/pnas.2112008119] [Reference Citation Analysis]
29 Oancea CN, Butaru AE, Streba CT, Pirici D, Rogoveanu I, Diculescu MM, Gheonea DI. Global hepatitis C elimination: history, evolution, revolutionary changes and barriers to overcome. Rom J Morphol Embryol 2021;61:643-53. [DOI: 10.47162/rjme.61.3.02] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
30 Yang R, Wei L. Profile of the VERSANT HCV genotype 2.0 assay. Expert Rev Mol Diagn 2018;18:995-1004. [PMID: 30372355 DOI: 10.1080/14737159.2018.1541740] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
31 Lothert K, Offersgaard AF, Pihl AF, Mathiesen CK, Jensen TB, Alzua GP, Fahnøe U, Bukh J, Gottwein JM, Wolff MW. Development of a downstream process for the production of an inactivated whole hepatitis C virus vaccine. Sci Rep 2020;10:16261. [PMID: 33004836 DOI: 10.1038/s41598-020-72328-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
32 Marascio N, Costantino A, Taffon S, Lo Presti A, Equestre M, Bruni R, Pisani G, Barreca GS, Quirino A, Trecarichi EM, Costa C, Mazzitelli M, Serapide F, Matera G, Torti C, Liberto MC, Ciccaglione AR. Phylogenetic and Molecular Analyses of More Prevalent HCV1b Subtype in the Calabria Region, Southern Italy. J Clin Med 2021;10:1655. [PMID: 33924449 DOI: 10.3390/jcm10081655] [Reference Citation Analysis]
33 Khan MA, Khan SA, Hamayun M, Ali M, Idrees M. Sequence variability of HCV 3a isolates based on core gene in patients from Lahore, Pakistan. Future Virology 2019;14:641-53. [DOI: 10.2217/fvl-2019-0086] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
34 Pronier C, Fontaine H, Dorival C, Carrat F, Pol S, Thibault V; AFEF/ANRS Hepather study group. Genetic diversity of genotype 6 HCV infections in France: Epidemiology and consequences for treatment strategy. J Viral Hepat 2019;26:1276-83. [PMID: 31273896 DOI: 10.1111/jvh.13171] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Hostager R, Ragonnet-Cronin M, Murrell B, Hedskog C, Osinusi A, Susser S, Sarrazin C, Svarovskaia E, Wertheim JO. Hepatitis C virus genotype 1 and 2 recombinant genomes and the phylogeographic history of the 2k/1b lineage. Virus Evol 2019;5:vez041. [PMID: 31616569 DOI: 10.1093/ve/vez041] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
36 Echeverría N, Comas V, Aldunate F, Perbolianachis P, Moreno P, Cristina J. In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet? . World J Hepatol 2021; 13(10): 1234-1268 [PMID: 34786164 DOI: 10.4254/wjh.v13.i10.1234] [Reference Citation Analysis]
37 Saludes V, Antuori A, Reinhardt B, Viciana I, Clavijo E, Schreiber L, Tenenbaum M, Rodriguez-Frias F, Quer J, Matas L, Martró E. Reliable resolution of ambiguous hepatitis C virus genotype 1 results with the Abbott HCV Genotype Plus RUO assay. Sci Rep 2019;9:3678. [PMID: 30842623 DOI: 10.1038/s41598-019-40099-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
38 Adeboyejo K, Grosche VR, José DP, Ferreira GM, Shimizu JF, King BJ, Tarr AW, Soares MMCN, Ball JK, Mcclure CP, Jardim ACG. Simultaneous determination of HCV genotype and NS5B resistance associated substitutions using dried serum spots from São Paulo state, Brazil. Access Microbiology 2022;4. [DOI: 10.1099/acmi.0.000326] [Reference Citation Analysis]
39 Li J, Zhou Q, Rong L, Rong D, Yang Y, Hao J, Zhang Z, Ma L, Rao G, Zhou Y, Xiao F, Li C, Wang H, Li YP. Development of cell culture infectious clones for hepatitis C virus genotype 1b and transcription analysis of 1b-infected hepatoma cells. Antiviral Res 2021;193:105136. [PMID: 34252495 DOI: 10.1016/j.antiviral.2021.105136] [Reference Citation Analysis]
40 Qi M, Yang M, Xu L, Ma C, Huang P, Sun J, Shi J, Hu Y. Complete genome analysis identifies recombinant events and positive selection sites of hepatitis C virus from mainland China during 2010-2019. Virus Res 2021;296:198354. [PMID: 33639223 DOI: 10.1016/j.virusres.2021.198354] [Reference Citation Analysis]
41 Davis C, Mgomella GS, da Silva Filipe A, Frost EH, Giroux G, Hughes J, Hogan C, Kaleebu P, Asiki G, McLauchlan J, Niebel M, Ocama P, Pomila C, Pybus OG, Pépin J, Simmonds P, Singer JB, Sreenu VB, Wekesa C, Young EH, Murphy DG, Sandhu M, Thomson EC. Highly Diverse Hepatitis C Strains Detected in Sub-Saharan Africa Have Unknown Susceptibility to Direct-Acting Antiviral Treatments. Hepatology 2019;69:1426-41. [PMID: 30387174 DOI: 10.1002/hep.30342] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
42 Witkowska McConnell W, Davis C, Sabir SR, Garrett A, Bradley-Stewart A, Jajesniak P, Reboud J, Xu G, Yang Z, Gunson R, Thomson EC, Cooper JM. Paper microfluidic implementation of loop mediated isothermal amplification for early diagnosis of hepatitis C virus. Nat Commun 2021;12:6994. [PMID: 34848705 DOI: 10.1038/s41467-021-27076-z] [Reference Citation Analysis]
43 Villar LM, de Paula VS, do Lago BV, Miguel JC, Cruz HM, Portilho MM, Marques VA, Ravier RP, Lo Castro I, Cuello H, Espul C. Epidemiology of hepatitis B and C virus infection in Central West Argentina. Arch Virol 2020;165:913-22. [PMID: 32078045 DOI: 10.1007/s00705-020-04540-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
44 Khedhiri M, Ghedira K, Chouikha A, Touzi H, Sadraoui A, Hammemi W, Triki H. Tracing the epidemic history of hepatitis C virus genotype 1b in Tunisia and in the world, using a Bayesian coalescent approach. Infect Genet Evol 2019;75:103944. [PMID: 31260787 DOI: 10.1016/j.meegid.2019.103944] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
45 Ranjbar Kermani F, Mousavi Hosseini K, Amini-kafiabad S, Maghsudlu M, Sharifi Z, Mansournia MA. Phylogenetic Analysis of NS5B Region of Hepatitis C Genotype 3a Virus among Different Risk Groups in Iran. Hepat Mon 2021;20. [DOI: 10.5812/hepatmon.108936] [Reference Citation Analysis]
46 Ashraf MU, Salman HM, Khalid MF, Khan MHF, Anwar S, Afzal S, Idrees M, Chaudhary SU. CRISPR-Cas13a mediated targeting of hepatitis C virus internal-ribosomal entry site (IRES) as an effective antiviral strategy. Biomed Pharmacother 2021;136:111239. [PMID: 33454599 DOI: 10.1016/j.biopha.2021.111239] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Velázquez-Moctezuma R, Augestad EH, Castelli M, Holmboe Olesen C, Clementi N, Clementi M, Mancini N, Prentoe J. Mechanisms of Hepatitis C Virus Escape from Vaccine-Relevant Neutralizing Antibodies. Vaccines (Basel) 2021;9:291. [PMID: 33804732 DOI: 10.3390/vaccines9030291] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Shah R, Ahovegbe L, Niebel M, Shepherd J, Thomson EC. Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens. J Hepatol 2021;75:462-73. [PMID: 33974951 DOI: 10.1016/j.jhep.2021.04.045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
49 Nazario de Moraes L, Tommasini Grotto RM, Targino Valente G, de Carvalho Sampaio H, Magro AJ, Fogaça L, Wolf IR, Perahia D, Faria Silva G, Plana Simões R. A novel molecular mechanism to explain mutations of the HCV protease associated with resistance against covalently bound inhibitors. Virus Res 2019;274:197778. [PMID: 31618615 DOI: 10.1016/j.virusres.2019.197778] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
50 Totsuka M, Honda M, Kanda T, Ishii T, Matsumoto N, Yamana Y, Kaneko T, Mizutani T, Takahashi H, Kumagawa M, Sasaki R, Masuzaki R, Kanezawa S, Nirei K, Yamagami H, Matsuoka S, Ohnishi H, Okamoto H, Moriyama M. Japanese Man with HCV Genotype 4 Infection and Cirrhosis Who Was Successfully Treated by the Combination of Glecaprevir and Pibrentasvir. Intern Med 2021;60:2061-6. [PMID: 33518580 DOI: 10.2169/internalmedicine.6728-20] [Reference Citation Analysis]
51 Chahal D, Marquez V, Hussaini T, Kim P, Chung SW, Segedi M, Chartier-Plante S, Scudamore CH, Erb SR, Salh B, Yoshida EM. End stage liver disease etiology & transplantation referral outcomes of major ethnic groups in British Columbia, Canada: A cohort study. Medicine (Baltimore) 2021;100:e27436. [PMID: 34678872 DOI: 10.1097/MD.0000000000027436] [Reference Citation Analysis]
52 Takagi A, Amako Y, Yamane D, Kitab B, Tokunaga Y, El-Gohary A, Kohara M, Tsukiyama-Kohara K. Longer Poly(U) Stretches in the 3'UTR Are Essential for Replication of the Hepatitis C Virus Genotype 4a Clone in in vitro and in vivo. Front Microbiol 2021;12:764816. [PMID: 34899647 DOI: 10.3389/fmicb.2021.764816] [Reference Citation Analysis]
53 Arca-Lafuente S, Martínez-Román P, Mate-Cano I, Madrid R, Briz V. Nanotechnology: A reality for diagnosis of HCV infectious disease. J Infect 2020;80:8-15. [PMID: 31580870 DOI: 10.1016/j.jinf.2019.09.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
54 Lanini S, Ustianowski A, Pisapia R, Zumla A, Ippolito G. Viral Hepatitis. Infectious Disease Clinics of North America 2019;33:1045-62. [DOI: 10.1016/j.idc.2019.08.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
55 Duncan JD, Urbanowicz RA, Tarr AW, Ball JK. Hepatitis C Virus Vaccine: Challenges and Prospects. Vaccines (Basel) 2020;8:E90. [PMID: 32079254 DOI: 10.3390/vaccines8010090] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
56 Quer J, Colomer-castell S, Campos C, Andrés C, Piñana M, Cortese MF, González-sánchez A, Garcia-cehic D, Ibáñez M, Pumarola T, Rodríguez-frías F, Antón A, Tabernero D. Next-Generation Sequencing for Confronting Virus Pandemics. Viruses 2022;14:600. [DOI: 10.3390/v14030600] [Reference Citation Analysis]
57 Fernández-Caso B, Fernández-Caballero JÁ, Chueca N, Rojo E, de Salazar A, García Buey L, Cardeñoso L, García F. Infection with multiple hepatitis C virus genotypes detected using commercial tests should be confirmed using next generation sequencing. Sci Rep 2019;9:9264. [PMID: 31239457 DOI: 10.1038/s41598-019-42605-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
58 Czarnota A, Offersgaard A, Pihl AF, Prentoe J, Bukh J, Gottwein JM, Bieńkowska-Szewczyk K, Grzyb K. Specific Antibodies Induced by Immunization with Hepatitis B Virus-Like Particles Carrying Hepatitis C Virus Envelope Glycoprotein 2 Epitopes Show Differential Neutralization Efficiency. Vaccines (Basel) 2020;8:E294. [PMID: 32532076 DOI: 10.3390/vaccines8020294] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
59 Ferreira AR, Ramos B, Nunes A, Ribeiro D. Hepatitis C Virus: Evading the Intracellular Innate Immunity. J Clin Med 2020;9:E790. [PMID: 32183176 DOI: 10.3390/jcm9030790] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
60 Mekonnen ZA, Grubor-Bauk B, English K, Leung P, Masavuli MG, Shrestha AC, Bertolino P, Bowen DG, Lloyd AR, Gowans EJ, Wijesundara DK. Single-Dose Vaccination with a Hepatotropic Adeno-associated Virus Efficiently Localizes T Cell Immunity in the Liver with the Potential To Confer Rapid Protection against Hepatitis C Virus. J Virol 2019;93:e00202-19. [PMID: 31292249 DOI: 10.1128/JVI.00202-19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
61 AlMalki WH, Shahid I, Abdalla AN, Johargy AK, Ahmed M, Hassan S. Virological surveillance, molecular phylogeny, and evolutionary dynamics of hepatitis C virus subtypes 1a and 4a isolates in patients from Saudi Arabia. Saudi J Biol Sci 2021;28:1664-77. [PMID: 33732052 DOI: 10.1016/j.sjbs.2020.11.089] [Reference Citation Analysis]
62 Schlotthauer F, McGregor J, Drummer HE. To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity. Viruses 2021;13:805. [PMID: 33946211 DOI: 10.3390/v13050805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Sokolova TM. [Hepatitis C virus (Flaviviridae: Hepacivirus: Hepacivirus C): regulation of signaling reactions of innate immunity]. Vopr Virusol 2021;65:307-16. [PMID: 33533227 DOI: 10.36233/0507-4088-2020-65-6-1] [Reference Citation Analysis]
64 Lee H, Chien RN, Pao LH, Kuo CJ, Huang PH, Chang ML. Decoupled Glucose and Lipid Metabolic Recovery after Viral Clearance in Direct-Acting Antiviral-Treated HCV Patients: A 3-Year Prospective Cohort Study. Cells 2021;10:2934. [PMID: 34831156 DOI: 10.3390/cells10112934] [Reference Citation Analysis]
65 Pisano MB, Giadans CG, Flichman DM, Ré VE, Preciado MV, Valva P. Viral hepatitis update: Progress and perspectives . World J Gastroenterol 2021; 27(26): 4018-4044 [PMID: 34326611 DOI: 10.3748/wjg.v27.i26.4018] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Brasher NA, Adhikari A, Lloyd AR, Tedla N, Bull RA. Hepatitis C Virus Epitope Immunodominance and B Cell Repertoire Diversity. Viruses 2021;13:983. [PMID: 34070572 DOI: 10.3390/v13060983] [Reference Citation Analysis]
67 Torre P, Aglitti A, Masarone M, Persico M. Viral hepatitis: Milestones, unresolved issues, and future goals. World J Gastroenterol 2021; 27(28): 4603-4638 [PMID: 34366625 DOI: 10.3748/wjg.v27.i28.4603] [Reference Citation Analysis]
68 Cabral BCA, Ramos JA, Silveira ALM, Nascimento ÉRDS, Ferreira SB, Coelho HSM, Moura-Neto RS, Villela-Nogueira CA, Hoffmann L, Silva R. Frequency distribution of HCV resistance-associated variants in infected patients treated with direct-acting antivirals. Int J Infect Dis 2021;115:171-7. [PMID: 34902582 DOI: 10.1016/j.ijid.2021.12.320] [Reference Citation Analysis]
69 Palladino C, Ezeonwumelu IJ, Mate-Cano I, Borrego P, Martínez-Román P, Arca-Lafuente S, Resino S, Taveira N, Briz V. Epidemic history and baseline resistance to NS5A-specific direct acting drugs of hepatitis C virus in Spain. Sci Rep 2020;10:13024. [PMID: 32747734 DOI: 10.1038/s41598-020-69692-7] [Reference Citation Analysis]
70 Chang ML, Hu JH, Pao LH, Lin MS, Kuo CJ, Chen SC, Fan CM, Chang MY, Chien RN. Critical role of triglycerides for adiponectin levels in hepatitis C: a joint study of human and HCV core transgenic mice. BMC Immunol 2021;22:54. [PMID: 34380427 DOI: 10.1186/s12865-021-00445-5] [Reference Citation Analysis]
71 Dehghani-dehej F, Hosseini Z, Mortazkar P, Khanaliha K, Esghaei M, Fakhim A, Bokharaei-salim F. Prevalence of HCV and/or HBV coinfection in Iranian HIV-infected patients. Future Virology 2020;15:155-63. [DOI: 10.2217/fvl-2019-0066] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Oestringer BP, Bolivar JH, Claridge JK, Almanea L, Chipot C, Dehez F, Holzmann N, Schnell JR, Zitzmann N. Hepatitis C virus sequence divergence preserves p7 viroporin structural and dynamic features. Sci Rep 2019;9:8383. [PMID: 31182749 DOI: 10.1038/s41598-019-44413-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
73 Chang ML, Chang SW, Chen SC, Chien RN, Hsu CL, Chang MY, Fann CSJ. Genetic Association of Hepatitis C-Related Mixed Cryoglobulinemia: A 10-Year Prospective Study of Asians Treated with Antivirals. Viruses 2021;13:464. [PMID: 33799903 DOI: 10.3390/v13030464] [Reference Citation Analysis]
74 Offersgaard A, Duarte Hernandez CR, Finne Pihl A, Prabhakar Venkatesan N, Krarup H, Lin X, Reichl U, Bukh J, Genzel Y, Gottwein JM. High-Titer Hepatitis C Virus Production in a Scalable Single-Use High Cell Density Bioreactor. Vaccines 2022;10:249. [DOI: 10.3390/vaccines10020249] [Reference Citation Analysis]
75 Kardani K, Sadat SM, Kardani M, Bolhassani A. The next generation of HCV vaccines: a focus on novel adjuvant development. Expert Rev Vaccines 2021;20:839-55. [PMID: 34114513 DOI: 10.1080/14760584.2021.1941895] [Reference Citation Analysis]
76 Roudot-Thoraval F. Epidemiology of hepatitis C virus infection. Clin Res Hepatol Gastroenterol 2021;45:101596. [PMID: 33610022 DOI: 10.1016/j.clinre.2020.101596] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
77 Ren J, Ojeda I, Patel M, Johnson ME, Lee H. Exploring small molecules with pan-genotypic inhibitory activities against hepatitis C virus NS3/4A serine protease. Bioorg Med Chem Lett 2019;29:2349-53. [PMID: 31201062 DOI: 10.1016/j.bmcl.2019.06.009] [Reference Citation Analysis]
78 Marascio N, Mazzitelli M, Scarlata GG, Giancotti A, Barreca GS, Lamberti AG, Divenuto F, Costa C, Trecarichi EM, Matera G, Liberto MC, Torti C. HCV Antibody Prevalence and Genotype Evolution in a Teaching Hospital, Calabria Region, Southern Italy Over A Decade (2008-2018). TOMICROJ 2020;14:84-90. [DOI: 10.2174/1874285802014010084] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Cox AL. Challenges and Promise of a Hepatitis C Virus Vaccine. Cold Spring Harb Perspect Med 2020;10:a036947. [PMID: 31548228 DOI: 10.1101/cshperspect.a036947] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
80 Gammeltoft KA, Zhou Y, Duarte Hernandez CR, Galli A, Offersgaard A, Costa R, Pham LV, Fahnøe U, Feng S, Scheel TKH, Ramirez S, Bukh J, Gottwein JM. Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro. Antimicrob Agents Chemother 2021;65:e0268020. [PMID: 34097489 DOI: 10.1128/AAC.02680-20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
81 Elsheikh MEA, McClure CP, Tarr AW, Irving WL. Sero-reactivity to three distinct regions within the hepatitis C virus alternative reading frame protein (ARFP/core+1) in patients with chronic HCV genotype-3 infection. J Gen Virol 2022;103. [PMID: 35230930 DOI: 10.1099/jgv.0.001727] [Reference Citation Analysis]
82 Isakov V, Hedskog C, Wertheim JO, Hostager RE, Parhy B, Schneider AB, Suri V, Mo H, Geivandova N, Morozov V, Bessonova E, Gankina N, Zhdanov K, Abdurakhmanov D, Svarovskaia E. Prevalence of resistance-associated substitutions and phylogenetic analysis of hepatitis C virus infection in Russia. Int J Infect Dis 2021;113:36-42. [PMID: 34560266 DOI: 10.1016/j.ijid.2021.09.041] [Reference Citation Analysis]
83 Chang ML, Lin YS, Chang MY, Hsu CL, Chien RN, Fann CS. Accelerated cardiovascular risk after viral clearance in hepatitis C patients with the NAMPT-rs61330082 TT genotype: An 8-year prospective cohort study. Virulence 2021;12:270-80. [PMID: 33446046 DOI: 10.1080/21505594.2020.1870080] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
84 Marascio N, Quirino A, Barreca GS, Galati L, Costa C, Pisani V, Mazzitelli M, Matera G, Liberto MC, Focà A, Torti C. Discussion on critical points for a tailored therapy to cure hepatitis C virus infection. Clin Mol Hepatol 2019;25:30-6. [PMID: 30669818 DOI: 10.3350/cmh.2018.0061] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
85 Ye M, Chen X, Wang Y, Duo L, Zhang C, Zheng YT. Identification of a New HCV Subtype 6xg Among Injection Drug Users in Kachin, Myanmar. Front Microbiol 2019;10:814. [PMID: 31057519 DOI: 10.3389/fmicb.2019.00814] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
86 Han B, Martin R, Xu S, Parvangada A, Svarovskaia ES, Mo H, Dvory-Sobol H. Sofosbuvir susceptibility of genotype 1 to 6 HCV from DAA-naïve subjects. Antiviral Res 2019;170:104574. [PMID: 31394118 DOI: 10.1016/j.antiviral.2019.104574] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
87 Wei S, Hu X, Du L, Zhao L, Xue H, Liu C, Chou JJ, Zhong J, Tong Y, Wang S, OuYang B. Inhibitor Development against p7 Channel in Hepatitis C Virus. Molecules 2021;26:1350. [PMID: 33802584 DOI: 10.3390/molecules26051350] [Reference Citation Analysis]
88 da Silva DL, Nunes HM, Freitas PEB. Natural prevalence of NS3 gene resistance-associated substitutions (RASs) in patients with chronic hepatitis C from the state of Pará/Brazil. Virus Res 2021;292:198251. [PMID: 33259871 DOI: 10.1016/j.virusres.2020.198251] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
89 Chen M, Xu Y, Li N, Yin P, Zhou Q, Feng S, Wu T, Wei L, Wang H, Fu Y, Li Y. Development of full-length cell-culture infectious clone and subgenomic replicon for a genotype 3a isolate of hepatitis C virus. Journal of General Virology 2021;102. [DOI: 10.1099/jgv.0.001704] [Reference Citation Analysis]
90 Amougou-Atsama M, Jean Adrien Atangana P, Noah Noah D, Fewou Moundipa P, Pineau P, Njouom R. The role of hepatitis C virus genotypes and core mutations in hepatocellular carcinoma in Cameroon. J Viral Hepat 2020;27:880-5. [PMID: 32301239 DOI: 10.1111/jvh.13303] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
91 Martinez MA, Franco S. Therapy Implications of Hepatitis C Virus Genetic Diversity. Viruses 2020;13:E41. [PMID: 33383891 DOI: 10.3390/v13010041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
92 Santander Ballestín S, Gómez Martín D, Lorente Pérez S, Luesma Bartolomé MJ. Hepatitis C: A Pharmacological Therapeutic Update. J Clin Med 2021;10:1568. [PMID: 33917830 DOI: 10.3390/jcm10081568] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
93 Rajhi M, Haddad-Boubaker S, Chouikha A, Bourquain D, Michel J, Hammami W, Sadraoui A, Touzi H, Ghedira K, Triki H. Identification of two novel hepatitis C virus subtype 2 from Tunisia (2v and 2w). PLoS One 2021;16:e0248249. [PMID: 33705445 DOI: 10.1371/journal.pone.0248249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Cagliani R, Forni D, Sironi M. Mode and tempo of human hepatitis virus evolution. Comput Struct Biotechnol J 2019;17:1384-95. [PMID: 31768229 DOI: 10.1016/j.csbj.2019.09.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
95 Uribe-Noguez LA, Mata-Marín JA, Ocaña-Mondragón A, Pompa-Mera EN, Ribas-Aparicio RM, Arroyo-Anduiza CI, Gomez-Torres ME, Chaparro-Sánchez A, Gaytán-Martínez J, Mauss S. Comparison of direct sequencing of the NS5B region with the Versant HCV genotype 2.0 assay for genotyping of viral isolates in Mexico. J Infect Chemother 2020;26:205-10. [PMID: 31537472 DOI: 10.1016/j.jiac.2019.08.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
96 Rao JR, Rafique S, Ali A, Rehman G, Ilyas M, Idrees M. Next-generation sequencing studies on the E1-HVR1 region of hepatitis C virus (HCV) from non-high-risk HCV patients living in Punjab and Khyber Pakhtunkhwa, Pakistan. Arch Virol 2021;166:3049-59. [PMID: 34448937 DOI: 10.1007/s00705-021-05203-x] [Reference Citation Analysis]
97 Teimoori A, Ebrahimi S, Keshtkar N, Khaghani S, Salmanzadeh S, Ghafari S. Prevalence and genetic diversity of HCV among HIV-1 infected individuals living in Ahvaz, Iran. BMC Infect Dis 2019;19:389. [PMID: 31068133 DOI: 10.1186/s12879-019-4052-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
98 Li J, Boix E. Host Defence RNases as Antiviral Agents against Enveloped Single Stranded RNA Viruses. Virulence 2021;12:444-69. [PMID: 33660566 DOI: 10.1080/21505594.2021.1871823] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
99 Douglas MW, Tay ES, Eden JS, George J. Hepatitis C Virus Genotype 8 Infection-Successful Treatment With Sofosbuvir/Velpatasvir. J Infect Dis 2019;220:720-2. [PMID: 30958539 DOI: 10.1093/infdis/jiz155] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
100 Hedskog C, Parhy B, Chang S, Zeuzem S, Moreno C, Shafran SD, Borgia SM, Asselah T, Alric L, Abergel A, Chen JJ, Collier J, Kapoor D, Hyland RH, Simmonds P, Mo H, Svarovskaia ES. Identification of 19 Novel Hepatitis C Virus Subtypes-Further Expanding HCV Classification. Open Forum Infect Dis 2019;6:ofz076. [PMID: 30949527 DOI: 10.1093/ofid/ofz076] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 11.3] [Reference Citation Analysis]
101 Martinez MA, Franco S. Discovery and Development of Antiviral Therapies for Chronic Hepatitis C Virus Infection. Adv Exp Med Biol 2021;1322:139-57. [PMID: 34258740 DOI: 10.1007/978-981-16-0267-2_6] [Reference Citation Analysis]
102 Liu Z, Mao X, Wu J, Yu K, Yang Q, Suo C, Lu M, Jin L, Zhang T, Chen X. World-wide Prevalence of Substitutions in HCV Genome Associated With Resistance to Direct-Acting Antiviral Agents. Clinical Gastroenterology and Hepatology 2021;19:1906-1914.e25. [DOI: 10.1016/j.cgh.2019.10.046] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
103 Marascio N, Rotundo S, Quirino A, Matera G, Liberto MC, Costa C, Russo A, Trecarichi EM, Torti C. Similarities, differences, and possible interactions between hepatitis E and hepatitis C viruses: Relevance for research and clinical practice . World J Gastroenterol 2022; 28(12): 1226-1238 [DOI: 10.3748/wjg.v28.i12.1226] [Reference Citation Analysis]
104 Dvory-Sobol H, Han B, Lu J, Yu M, Beran RK, Cheng G, Martin R, Svarovskaia E, Mo H. In vitro resistance profile of hepatitis C virus NS5A inhibitor velpatasvir in genotypes 1 to 6. J Viral Hepat 2019;26:991-1001. [PMID: 31009123 DOI: 10.1111/jvh.13116] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
105 Nouhin J, Iwamoto M, Prak S, Dousset JP, Phon K, Heng S, Kerleguer A, Le Paih M, Dussart P, Maman D, Rouet F. Molecular epidemiology of hepatitis C virus in Cambodia during 2016-2017. Sci Rep 2019;9:7314. [PMID: 31086236 DOI: 10.1038/s41598-019-43785-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
106 Bradshaw D, Mbisa JL, Geretti AM, Healy BJ, Cooke GS, Foster GR, Thomson EC, McLauchlan J, Agarwal K, Sabin C, Mutimer D, Moss P, Irving WL, Barnes E; Hepatitis C Trust, UK. Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group. J Infect 2019;79:503-12. [PMID: 31629015 DOI: 10.1016/j.jinf.2019.10.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
107 Bellocchi MC, Aragri M, Carioti L, Fabeni L, Pipitone RM, Brancaccio G, Sorbo MC, Barbaliscia S, Di Maio VC, Bronte F, Grimaudo S, Mazzucco W, Frigeri F, Cantone M, Pinto A, Perno CF, Craxì A, Gaeta GB, Di Marco V, Ceccherini-Silberstein F. NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients. Cells 2019;8:E666. [PMID: 31269695 DOI: 10.3390/cells8070666] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
108 Mei X, Lu H. Prevalence, diagnosis, and treatment of hepatitis C in Mainland China. Glob Health Med 2021;3:270-5. [PMID: 34782868 DOI: 10.35772/ghm.2021.01080] [Reference Citation Analysis]
109 Ramirez S, Bukh J. Current status and future development of infectious cell-culture models for the major genotypes of hepatitis C virus: Essential tools in testing of antivirals and emerging vaccine strategies. Antiviral Res 2018;158:264-87. [PMID: 30059723 DOI: 10.1016/j.antiviral.2018.07.014] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
110 Kalita D, Deka S, Chamuah K. Circulation of an atypical hepatitis C virus (HCV) strain at a dialysis unit in northeast India. Microbiologyopen 2021;10:e1147. [PMID: 33369206 DOI: 10.1002/mbo3.1147] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
111 Torres-vázquez B, María de Lucas A, García-crespo C, Antonio García-martín J, Fragoso A, Fernández-algar M, Perales C, Domingo E, Moreno M, Briones C. In vitro selection of high affinity DNA and RNA aptamers that detect hepatitis C virus core protein of genotypes 1 to 4 and inhibit virus production in cell culture. Journal of Molecular Biology 2022. [DOI: 10.1016/j.jmb.2022.167501] [Reference Citation Analysis]
112 Nasimzadeh S, Azaran A, Jalilian S, Makvandi M, Seyedian SS, Keikhaei B, Mehr FJ. Prevalence of occult hepatitis C virus infection in beta-thalassemia major patients in Ahvaz, Iran. Arch Virol 2021;166:2703-10. [PMID: 34275067 DOI: 10.1007/s00705-021-05126-7] [Reference Citation Analysis]